The announcement of worse-than-expected Q4 financial results and the issuance of weaker FY24 EPS guidance directly impacts investor sentiment and the stock's value. Given the direct correlation between earnings reports, guidance, and stock performance, it's likely that Sanofi's stock will experience downward pressure in the short term.